Cargando…
Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
Objective: To develop and validate a prediction model for the pathological complete response (pCR) to neoadjuvant chemotherapy (NCT) of triple-negative breast cancer (TNBC). Methods: We systematically searched Gene Expression Omnibus, ArrayExpress, and PubMed for the gene expression profiles of oper...
Autores principales: | Han, Yiqun, Wang, Jiayu, Xu, Binghe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778555/ https://www.ncbi.nlm.nih.gov/pubmed/33403050 http://dx.doi.org/10.7150/jca.52439 |
Ejemplares similares
-
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023) -
Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2023) -
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
por: Gass, Paul, et al.
Publicado: (2018) -
A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2021) -
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023)